Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure.

@article{Roig2000ClinicalIO,
  title={Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure.},
  author={E. D. Almenar Roig and Felix Perez-Villa and Maria-Aurora Morales and Wladimiro Jim{\'e}nez and Josefina Or{\'u}s and Manuel Fern{\'a}ndez Heras and Mª Jes{\'u}s Zurbano},
  journal={European heart journal},
  year={2000},
  volume={21 1},
  pages={
          53-7
        }
}
AIMS The aim of the study was to assess the incidence and clinical implications of increased plasma angiotensin II despite chronic ACE inhibitor therapy in patients with heart failure. METHODS AND RESULTS The studied population consisted of 70 patients (mean age 59+/-9 years). Plasma renin activity and plasma concentration of aldosterone, norepinephrine, atrial natriuretic peptide, angiotensin II, tumour necrosis factor, interleukin-6 and interleukin-1B were assessed at 6 months of ACE… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 98 CITATIONS, ESTIMATED 45% COVERAGE

Angiotensin II, sympathetic nerve activity and chronic heart failure

  • Heart Failure Reviews
  • 2012
VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Sacubitril/valsartan (LCZ696) significantly reduces aldosterone and increases cGMP circulating levels in a canine model of RAAS activation.

  • European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
  • 2019
VIEW 1 EXCERPT
CITES BACKGROUND

FILTER CITATIONS BY YEAR

2000
2019

CITATION STATISTICS

  • 4 Highly Influenced Citations

  • Averaged 6 Citations per year from 2017 through 2019